AKEK Statement (Aug 2023): https://www.akek.de/wp-content/uploads/Stellungnahme-EHDS_V7.1.pdf
The Working Group of Medical Ethics Commissions in Germany (AKEK) has emphasized the importance of secondary patient data use for research in public health. Its relevance was magnified during the COVID-19 pandemic, showing the need for efficient data collection and evaluation. Germany requires a robust regulatory framework promoting both data privacy and research.
During the pandemic, the lack of standardization in country-specific regulations made data handling challenging. The upcoming European Health Data Space Regulation (EHDS-R) and the proposed German Health Data Use Act (Gesundheitsdatennutzungsgesetz – GDNG) aim to harmonize regulations, facilitating responsible health data access at multiple governance levels.
The pandemic also spurred interest in alternative consent models, like “broad consent” and “dynamic consent”, aiming to balance personal data rights, research freedom, and public health. As obtaining individual consent becomes complex, the German law needs clear rules to reconcile these rights.
Germany’s legislators need to evaluate consent models, considering pandemic-driven challenges. They should provide compensatory measures, such as defining standards for data pseudonymisation and anonymisation. Ensuring transparency in research results and balancing intellectual property rights are also vital.
For effective secondary patient data use in research, a strong governance structure, inclusive of ethics committees, is essential. These committees are pivotal in ensuring data protection and balancing the risks and benefits of research.
AKEK highlights key demands for promoting secondary patient data use:
- Nationwide standardisation of legal regulations to reduce bureaucratic hurdles.
- A balance between individual data rights, research freedom, and societal welfare.
- Risk-adapted methods to reconcile scientific evidence with data privacy.
- The involvement of ethics committees in governance for a balanced approach.
In conclusion, secondary patient data use is crucial for medical advancements. Germany needs a comprehensive strategy that balances individual rights with research benefits. The urgency brought by the COVID-19 pandemic necessitates swift legislative action by Germany.
Share this story...
Real World Evidence (RWE) 201…THE END – A Landscape Analysis of Regional RWE Frameworks – The European Health Data Space and DARWIN-EU
RWE 201 - THE END - A Landscape Analysis of Regional RWE Frameworks - The European Health Data Space and DARWIN-EU In our real world evidence (RWE) 201 series [...]
Real World Evidence (RWE) – Event Horizon
RWE 201 - RWE Event Horizon The term "event horizon" in the context of pharmaceuticals, particularly when discussing the shift towards real-world evidence (RWE) in regulatory submissions, is metaphorically [...]
Real World Evidence (RWE) 201 – Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development
RWE 201 - Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development Australia has several real-world evidence (RWE) initiatives to support healthcare [...]
Real World Evidence (RWE) 201 – South Korea’s Pioneering Approach: Integrating Real-World Evidence in Healthcare and Drug Development
RWE 201 - South Korea's Pioneering Approach: Integrating Real-World Evidence in Healthcare and Drug Development South Korea has several initiatives to support healthcare and drug development using [...]
Real World Evidence (RWE) 201 – Taiwan: Integrating Real-World Evidence for Drug Development and Policy Making
RWE 201 - Taiwan: Integrating Real-World Evidence for Drug Development and Policy Making Taiwan has several real-world evidence (RWE) initiatives to support healthcare and drug development. Over the past [...]
Real World Evidence (RWE) 201 – Revolutionizing Healthcare in Japan: The Rise of Real-World Evidence in Drug Development
RWE 201 - Revolutionizing Healthcare in Japan: The Rise of Real-World Evidence in Drug Development Japan has several initiatives to support healthcare and drug development using real-world evidence (RWE). [...]